ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference

Rhea-AI Summary

ADC Therapeutics SA (NYSE:ADCT), an oncology-focused biotech company, announced that CEO Chris Martin will participate in a fireside chat at the Cowen 41^st Annual Health Care Conference on March 4, 2021, at 12:50 p.m. ET. A live webcast will be available on the company's Investors page, with a replay accessible for 30 days. ADC Therapeutics specializes in antibody drug conjugates for hematological malignancies and solid tumors, leveraging proprietary PBD technology in their clinical pipeline, which includes promising candidates Loncastuximab tesirine and Camidanlumab tesirine.

ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at the Cowen 41^st Annual Health Care Conference on Thursday, March 4, 2021, at 12:50 p.m. ET.

A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics SA (NYSE:ADCT) is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company develops ADCs by applying its decades of experience in this field and using next-generation pyrrolobenzodiazepine (PBD) technology to which ADC Therapeutics has proprietary rights for its targets. Strategic target selection for PBD-based ADCs and substantial investment in early clinical development have enabled ADC Therapeutics to build a deep clinical and research pipeline of therapies for the treatment of hematological and solid tumor cancers. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to confirmatory Phase 3 clinical trials, in the USA and Europe, and numerous preclinical ADCs in development.

Loncastuximab tesirine (Lonca, formerly ADCT-402), the Company’s lead product candidate, has been evaluated in a 145-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that showed a 48.3% overall response rate (ORR), which exceeded the target primary endpoint. On November 20, 2020, the U.S. Food and Drug Administration accepted the Biologics License Application, granting priority review and setting a Prescription Drug User Fee Act (PDUFA) target action date of May 21, 2021. Camidanlumab tesirine (Cami, formerly ADCT-301), the Company’s second lead product candidate, is being evaluated in a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma (HL) for which preliminary data have demonstrated an 83% ORR, consistent with the Phase 1 clinical trial. The Company is also evaluating Cami in a Phase 1b clinical trial as a novel immuno-oncology approach for the treatment of various advanced solid tumors.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005286/en/

FAQ

When will Chris Martin speak at the Cowen 41st Annual Health Care Conference for ADCT?

Chris Martin, CEO of ADC Therapeutics, will participate in a fireside chat on March 4, 2021, at 12:50 p.m. ET.

How can I watch the ADC Therapeutics fireside chat?

The fireside chat will be available via a live webcast on the Investors page of ADC Therapeutics' website.

What is the target action date for ADCT's lead product Loncastuximab tesirine?

The target action date for Loncastuximab tesirine is May 21, 2021.

What is the overall response rate for Loncastuximab tesirine in its Phase 2 trial?

Loncastuximab tesirine showed a 48.3% overall response rate in its pivotal Phase 2 clinical trial.

What is Camidanlumab tesirine being evaluated for?

Camidanlumab tesirine is in a Phase 2 trial for the treatment of relapsed or refractory Hodgkin lymphoma, showing an 83% overall response rate.